Category: isoquinoline

On April 30, 2021, Wang, Dao-Cai; Yan, Ting-Ting; Chen, Bin; Liu, Feng; Liu, Xiao-Peng; Xie, Yong-Mei published an article.Name: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one The title of the article was SIS3, a good candidate for the reverse of type 2 diabetes mellitus in mice. And the article contained the following:

TGF-β signaling plays an extremely important role in the occurrence and development of type 2 diabetes mellitus (T2DM), and the blockade of TGF-b/Smad3 pathway protests against the high-fat diet-induced obesity and diabetes. As a specific small mol. inhibitor of Smad3 protein, the biol. activities of compound SIS3 were evaluated by high-fat diet-induced T2DM model mice. In vivo results indicated that SIS3 can not only significantly reduce the body weight, fat mass, and fasting blood glucose in high-fat diet-induced T2DM model mice, but also improve insulin sensitivity and oral glucose tolerance of high-fat diet-induced T2DM model mice after the injection of SIS3 with 5 mg/kg for 45 days. The experimental process involved the reaction of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one(cas: 1009104-85-1).Name: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

The Article related to compound sis diabetes mellitus mouse, sis3, smad3 inhibitor, treatment, type 2 diabetes mellitus, Pharmacology: Effects Of Agents For Treating Metabolic and Endocrine Disorders and other aspects.Name: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On May 29, 1991, Gueremy, Claude; Malleron, Jean Luc; Mignani, Serge published a patent.Recommanded Product: 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation and formulation of 2-[4-(indolylmethyl)piperidinoethyl]naphthoisothiazole-1,1-dioxides and analogs as serotonin (5HP) reuptake inhibitors. And the patent contained the following:

R1(CH2)nQ [I; Q = Z3R3, Z4R4; R1 = anellated isothiazolo groups Q1-Q3, RSO2N(Z), etc.; R = 2-naphthyl; R3 = 1-indenyl, 1-indanyl, (CH2)mR2, etc.; R2 = indolyl, indanyl, indenyl, quinolyl, etc.; R4 = (CH2)mR2; Y = H, alkyl, alkoxy, Ph; Z = alkyl; Z1 = SO2, CO; Z2 = CH; Z2 may also = N when Z1 = SO2; Z3 = piperidine-1,4-diyl; Z4 = piperazine-1,4-diyl, 1,2,3,6-tetrahydropyridine-1,4-diyl; m = 1, 2; n = 2, 3] were prepared Thus, BrCH2CH2Cl was condensed with 1,8-naphthosultam and the product condensed with 4-[(5-fluoro-3-indolyl)methyl]piperidine to give, after N-methylation, title compound II. I had IC50 < 25 nM for binding of paroxetine (substrate not given). The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 4-Bromo-5-nitroisoquinoline

The Article related to naphthoisothiazole indolylmethylpiperidinoethyl serotonin reuptake inhibitor, indolylmethylpiperidinoethylnaphthoisothiazole preparation serotonin reuptake inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Recommanded Product: 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On January 10, 1990, Comte, Marie Therese; Gueremy, Claude; Malleron, Jean Luc; Mignani, Serge; Peyronel, Jean Francois; Truchon, Alain published a patent.Recommanded Product: 58142-46-4 The title of the patent was Preparation and formulation of (aza)naphthalenesultam derivatives as serotoninergic antagonists. And the patent contained the following:

Title compounds I [R1 = 4-(hetero)aryl-substituted 1,2,3,6-tetrahydro-1-pyridyl, 1-piperazinyl, or piperidino; R2, R3 = H, halo, R4 = H; or R2 = R4 = H, R3 = halo, AcNH; or R2 = R3 = H, R4 = halo, all with X = CH; or R2 = R3 = R4 = H, X = N; Z = (un)substituted alkylene; various provisos] were prepared as serotonergic 5-HT2 receptor antagonists (no data). Thus, N-alkylation of 1,8-naphthosultam by Br(CH2)3Cl using NaH in DMF gave the N-(3-chloropropyl) derivative, which reacted with 1-(4-fluorophenyl)piperazine in PhMe containing Et3N to give (piperazinylpropyl)naphthoisothiazole derivative II. Three formulations and 61 syntheses are given. The IC50 of I for displacement of [3H]-ketanserin from 5-HT receptors are said to be generally <25 nM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 58142-46-4

The Article related to naphthalenesultam preparation serotoninergic antagonist, naphthoisothiazole preparation 5ht antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Recommanded Product: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 28, 2005, Taveras, Arthur G.; Zheng, Junying; Biju, Purakkattle J.; Yu, Younong; Chao, Jianhua; Fine, Jay; Lundell, Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J. Robert; Baldwin, John J.; Lai, Gaifa; Wu, Minglang published a patent.Electric Literature of 74904-29-3 The title of the patent was Preparation of isothiazole dioxides as CXC- and CC-chemokine receptor ligands. And the patent contained the following:

Disclosed are novel compounds I [D, E = N, CR50; provided that D and E are not the same (one is N and the other is CR50); R50 = H, CF3, CN, etc.; A = (hetero)aryl, (hetero)arylalkyl; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 68% yield from the isothiazoledioxide III and the amine IV.pTSA (preparation of reactants given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Electric Literature of 74904-29-3

The Article related to isothiazole dioxide preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7 and other aspects.Electric Literature of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On September 2, 2005, Yamada, Rintaro; Seto, Minoru published a patent.Related Products of 58142-46-4 The title of the patent was Preparation of isoquinoline derivatives as inhibitors of myosins light chain phosphorylation. And the patent contained the following:

The title compounds I [wherein R1 = H, halo, OH, NH2, or alkoxy; R2 = H, halo, alkyl, etc.; R3 = (un)substituted OH, NH2, or SO2NH2] or salts thereof are prepared as inhibitors of myosins light chain phosphorylation for the treatment of glaucoma, chronic obstructive pulmonary disease, asthma, etc. For example, the compound II•xHCl was prepared II•xHCl inhibited human myosins light chain phosphorylation with IC50 of 0.8 μM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Related Products of 58142-46-4

The Article related to isoquinoline preparation inhibitor myosin regulatory light chain phosphorylation obstruction, human treatment glaucoma chronic obstructive pulmonary disease asthma, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Related Products of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On May 14, 2020, Lee, Matthew Randolph; Varano, Anthony Joseph published a patent.Reference of 4-Bromo-5-nitroisoquinoline The title of the patent was Sulfonylisoquinoline derivatives as Rock kinase inhibitors and their preparation. And the patent contained the following:

The invention relates to compounds of formula I as Rho-associated protein kinases (ROCK) inhibitors useful for treatment of cerebral cavernous malformation syndrome and cardiovascular diseases. Compounds of formulas I and II wherein ring X is partially saturated aza-containing heteroaryl; Y is CH or N; m is 0, 1, 2 and 3; each R1 is independently CN, OH, hydroxyalkyl, halo, etc.; R2 is H and halo; R3 is H, halo and C1-3 alkyl; with provisions; and pharmaceutically acceptable salts thereof, are claimed. Example compound III was prepared by sulfonylation of 1-chloroisoquinoline with chlorosulfonic acid; the resulting 1-chloroisoquinoline-5-sulfonyl chloride underwent hydrolysis to give 1-hydroxyisoquinoline-5-sulfonic acid, which underwent chlorination to give the corresponding sulfonyl chloride, which underwent amidation with 4-methylisoindoline to give compound III. Exemplified I were evaluated for selective ROCK kinase inhibitory activity from which III demonstrated IC50 values in the range of >1000 nM and ≤10,000 nM for both ROCK1 and ROCK2 compared to IC50 values of >10,000 for PKACA, AKT1, and PKG, resp. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Reference of 4-Bromo-5-nitroisoquinoline

The Article related to sulfonylisoquinoline derivative preparation rock kinase inhibitor cavernous malformation syndrome, selective rock1 rock2 inhibitor cardiovascular disease, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Reference of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 2, 2000, Mewshaw, Richard Eric; Meagher, Kristin Lynne published a patent.Computed Properties of 74904-29-3 The title of the patent was Preparation of tetrahydroisoquinolinylindole derivatives for the treatment of depression. And the patent contained the following:

The title compounds I [R1-R4 = H, halo, alkoxy, carboxamide; R5 = H, halo, CF3, CN, carbamide, alkoxy; X = (CH2)n, 4-6 membered carbocyclic ring, wherein n is an integer of 2 to 4], useful for the treatment of depression, were prepared E.g., 3-[(1,4-cis)-4-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)cyclohexyl]-1H-indole-5-carbonitrile was prepared by reaction of 7-methoxy-1,2,3,4-tetrahydroisoquinoline (preparation given) with 4-(5-cyano-1H-3-indolyl)cyclohexanone in presence of sodium triacetoxyborohydride and acetic acid in CH2Cl2. I are active towards 5HT1A receptors and generally elevate serotonin levels by inhibiting 5-HT transport. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Computed Properties of 74904-29-3

The Article related to isoquinolinylindole preparation depression treatment, indole isoquinolinyl preparation depression treatment, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Computed Properties of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Sall, Daniel J.; Grunewald, Gary L. published an article in 1987, the title of the article was Inhibition of phenylethanolamine N-methyltransferase (PNMT) by aromatic hydroxy-substituted 1,2,3,4-tetrahydroisoquinolines. Further studies on the hydrophilic pocket of the aromatic ring binding region of the active site.Related Products of 74904-29-3 And the article contains the following content:

In a study directed toward characterizing the hydrophilic pocket within the aromatic ring binding region of the active site of phenylethanolamine N-methyltransferase (PNMT), 5-, 6-, 7-, and 8-hydroxy-1,2,3,4-tetrahydroisoquinoline were prepared and evaluated as substrates and inhibitors of PNMT. Thus, 2-MeOC6H4CH2CH2NHCO2Me was cyclized by polyphosphoric acid to give 8-methoxy-3,4-dihydroisoquinolin-1-one, which was reduced followed by demethylation to give 8-hydroxy-1,2,3,4-tetrahydroisoquinoline. In order to discern the necessity of an acidic hydrogen for interaction at this pocket the corresponding Me ethers were also evaluated. The enhanced affinity of 7-hydroxy-1,2,3,4-tetrahydroisoquinoline vs. tetrahydroisoquinoline itself indicates that a hydrophilic pocket exists off of carbon C7 in bound tetrahydroisoquinolines. The Me ethers of 5-, 6-, 7-, and 8-hydroxy-exo-2-aminobenzonorbornene and of 5- and 6-hydroxy-anti-9-aminobenzonorbornene were also evaluated for their activity as substrates and inhibitors for PNMT. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to isoquinolinol tetrahydro preparation pnmt inhibition, phenylethanolamine methyltransferase inhibition, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 30, 2013, Abate, Carmen; Selivanova, Svetlana V.; Muller, Adrienne; Kramer, Stefanie D.; Schibli, Roger; Marottoli, Roberta; Perrone, Roberto; Berardi, Francesco; Niso, Mauro; Ametamey, Simon M. published an article.Related Products of 74904-29-3 The title of the article was Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors. And the article contained the following:

σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their d. With the aim of contributing to the research of σ2 receptor Positron Emission Tomog. (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3,4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacol. properties and appropriate lipophilicity. Hence, 3 served as the lead compound for the development of a series of dihydroisoquinolinones amenable to radiolabeling. Radiosynthesis for compound 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiog. on rat brain slices. Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp. Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to brain, homo sapiens, human, positron emission tomography, tomography imaging agents, tumor imaging, σ1-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study), σ2-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study) and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 5, 2004, Taveras, Arthur G.; Aki, Cynthia J.; Chao, Jianping; Dwyer, Michael; Chao, Jianhua; Yu, Younong; Merritt, J. Robert; Biju, Purakkattle; Jakway, James; Lai, Gaifa; Wu, Minglang; Hecker, Evan A.; Lundell, Daniel; Fine, Jay S. published a patent.Product Details of 74904-29-3 The title of the patent was Preparation of 3,4-di(substituted amino)cyclobutene-1,2-diones as CXC-chemokine receptor ligands. And the patent contained the following:

Disclosed are novel compounds of the formula (I) or pharmaceutically acceptable salts or solvates thereof [A = Q, Q1; B = substituted Ph, (un)substituted 1H-pyrazol-3-yl, 1H-pyrazol-5-yl, 2- or 3-thienyl, 1H-pyrrol-3-yl, 1H-pyrrol-2-yl, isothiazol-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-3-yl, 4-hydroxypyrimidin-4-yl, or 4-hydroxypyridin-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-5-yl, 1,4-dihydro-1-hydroxy-4-oxopyridin-2-yl, 1H-benzotriazol-7-yl, 1H-benzimidazol-7-yl, 1H-indol-7-yl, or benzo[c]pyrazol-7-yl; R7, R8 = H, each (un)substituted alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, CO2H, CONH2, alkynyl, alkenyl, cycloalkenyl; R12 = H,each (un)substituted CO2H, aryl, heteroaryl, arylalkyl, cycloalkyl, alkyl, cycloalkylalkyl, or heteroarylalkyl group]. Also disclosed is the treatment of chemokine-mediated diseases, where the chemokine binds to CXCR2 and/or CXCR1 receptor, using compounds of the formula I. The diseases include chronic inflammation, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, chronic neuropathic pain, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, septic shock, endotoxic shock, gram neg. sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, Alzheimer’s disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis, cerebral and cardiac ischemia, osteoarthritis, multiple sclerosis, restenosis, angiogenesis, osteoporosis, gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi’s sarcoma associated virus, meningitis, cystic fibrosis, preterm labor, cough, pruritis, multiorgan dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, and subarachnoid hemorrhage. They also include post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alc. hepatitis, necrotizing enterocolitis, chronic sinusitis, angiogenic ocular disease, ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, cough, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), granulocytic ehrlichiosis, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds, gout, alc. liver disease, lupus, burn therapy, periodontitis, transplant reperfusion injury and early transplantation rejection, acute inflammation, and rheumatoid arthritis as well as cancer. The compounds I had IC50 of <10 μM for inhibiting the binding of [125I]-IL-8 to human chemokine receptor CXCR1. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Product Details of 74904-29-3

The Article related to aminocyclobutenedione preparation cxc chemokine receptor ligand, inflammation treatment aminocyclobutenedione preparation, inflammatory pain treatment aminocyclobutenedione preparation, cancer treatment aminocyclobutenedione preparation, psoriasis treatment aminocyclobutenedione preparation, atopic dermatitis treatment aminocyclobutenedione preparation and other aspects.Product Details of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem